Curbstone Financial Management Corp trimmed its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report) by 15.4% in the second quarter, according to its most recent filing with the SEC. The firm owned 6,050 shares of the medical instruments supplier’s stock after selling 1,100 shares during the period. Curbstone Financial Management Corp’s holdings in LeMaitre Vascular were worth $502,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Principal Financial Group Inc. lifted its holdings in shares of LeMaitre Vascular by 3.0% during the 1st quarter. Principal Financial Group Inc. now owns 111,865 shares of the medical instruments supplier’s stock worth $9,385,000 after acquiring an additional 3,248 shares during the period. US Bancorp DE lifted its holdings in shares of LeMaitre Vascular by 36.0% during the 1st quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier’s stock worth $117,000 after acquiring an additional 368 shares during the period. Johnson Investment Counsel Inc. increased its position in shares of LeMaitre Vascular by 34.8% during the 1st quarter. Johnson Investment Counsel Inc. now owns 29,428 shares of the medical instruments supplier’s stock worth $2,469,000 after purchasing an additional 7,603 shares in the last quarter. Consolidated Planning Corp acquired a new stake in shares of LeMaitre Vascular during the 1st quarter worth about $947,000. Finally, Northern Trust Corp increased its position in shares of LeMaitre Vascular by 5.4% during the 1st quarter. Northern Trust Corp now owns 345,563 shares of the medical instruments supplier’s stock worth $28,993,000 after purchasing an additional 17,748 shares in the last quarter. 84.64% of the stock is owned by institutional investors.
Insider Buying and Selling at LeMaitre Vascular
In other news, Director Bridget A. Ross sold 2,500 shares of LeMaitre Vascular stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $94.00, for a total transaction of $235,000.00. Following the completion of the sale, the director owned 2,916 shares in the company, valued at $274,104. The trade was a 46.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director John A. Roush sold 6,561 shares of LeMaitre Vascular stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $92.55, for a total transaction of $607,220.55. Following the sale, the director owned 2,916 shares of the company’s stock, valued at approximately $269,875.80. This represents a 69.23% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 120,815 shares of company stock worth $11,280,206 in the last 90 days. Corporate insiders own 9.50% of the company’s stock.
LeMaitre Vascular Trading Down 0.3%
LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.03. The firm had revenue of $63.15 million during the quarter, compared to analysts’ expectations of $62.48 million. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The company’s quarterly revenue was up 15.0% compared to the same quarter last year. During the same quarter last year, the company posted $0.52 EPS. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. As a group, equities analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.
LeMaitre Vascular Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Thursday, September 4th. Stockholders of record on Thursday, August 21st were given a dividend of $0.20 per share. The ex-dividend date was Thursday, August 21st. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. LeMaitre Vascular’s payout ratio is currently 38.83%.
Analyst Ratings Changes
A number of equities research analysts recently issued reports on LMAT shares. Weiss Ratings reiterated a “buy (b-)” rating on shares of LeMaitre Vascular in a research report on Wednesday, October 8th. Barrington Research reiterated an “outperform” rating and set a $95.00 target price on shares of LeMaitre Vascular in a research report on Wednesday. Finally, Cantor Fitzgerald increased their target price on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Three investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $97.60.
View Our Latest Research Report on LeMaitre Vascular
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.
Featured Stories
- Five stocks we like better than LeMaitre Vascular
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Johnson & Johnson’s M&A Strategy Is the Real Story for Investors
- Most Volatile Stocks, What Investors Need to Know
- Tesla: Some Analysts Are Calling for A 30% Drop—Time to Panic?
- How to Evaluate a Stock Before Buying
- Hedge Funds Flip on the Dollar—A Buy Signal for These 3 Stocks?
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.